- Home
- NXTC vs NEUP Comparison
NXTC vs NEUP Comparison
Compare NXTC & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- NEUP
- Stock Information
- Founded
- NXTC 2015
- NEUP 1996
- Country
- NXTC United States
- NEUP United States
- Employees
- NXTC N/A
- NEUP N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- NXTC Health Care
- NEUP
- Exchange
- NXTC Nasdaq
- NEUP Nasdaq
- Market Cap
- NXTC 12.8M
- NEUP 12.7M
- IPO Year
- NXTC 2019
- NEUP N/A
- Fundamental
- Price
- NXTC $4.85
- NEUP $11.89
- Analyst Decision
- NXTC Strong Buy
- NEUP Strong Buy
- Analyst Count
- NXTC 2
- NEUP 1
- Target Price
- NXTC $25.50
- NEUP $21.00
- AVG Volume (30 Days)
- NXTC 18.5K
- NEUP 67.0K
- Earning Date
- NXTC 11-06-2025
- NEUP 08-28-2025
- Dividend Yield
- NXTC N/A
- NEUP N/A
- EPS Growth
- NXTC N/A
- NEUP N/A
- EPS
- NXTC N/A
- NEUP 0.00
- Revenue
- NXTC N/A
- NEUP $15,662,715.00
- Revenue This Year
- NXTC N/A
- NEUP N/A
- Revenue Next Year
- NXTC N/A
- NEUP N/A
- P/E Ratio
- NXTC N/A
- NEUP $3.84
- Revenue Growth
- NXTC N/A
- NEUP N/A
- 52 Week Low
- NXTC $2.69
- NEUP $2.90
- 52 Week High
- NXTC $19.20
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- NXTC 41.16
- NEUP 67.40
- Support Level
- NXTC $4.83
- NEUP $6.82
- Resistance Level
- NXTC $5.15
- NEUP $13.25
- Average True Range (ATR)
- NXTC 0.23
- NEUP 1.32
- MACD
- NXTC -0.02
- NEUP 0.44
- Stochastic Oscillator
- NXTC 7.14
- NEUP 77.78
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.